Home
Congress Co-Chairpersons
Welcome Note
International Advisory Board
Program
Thursday, May 03
Friday, May 04
Saturday, May 05
Sunday, May 6
Timetable
Congress Information
Faculty List
Abstract Submission
Poster Display Guidelines
CME
General Information
Partners & Links
Italian Agent
Chinese Agent
About Barcelona
List of Posters - Group A
List of Posters - Group B
Before you travel...
Registration & Accommodation
Registration
Accommodation
Princesa Sofia Hotel
Invitation letter
Sponsorship & Exhibition
Exhibition
Sponsors
Exhibitors
Sponsorship Prospectus
2011 Sponsors
Contact Us
  Scientific Program - Saturday
Print

Thursday

Friday

Saturday

Sunday


Saturday, May 5, 2012 GYNECOLOGY
Session 13
08:30-10:00
SAFETY OF ORAL CONTRACEPTION: TIME TO LOOK AGAIN AT THE EVIDENCE
Capsule: First and foremost, a discussion of contraceptive safety is perhaps the hottest topic today
Chairperson: F. Martinez, Spain; H. Coelingh Bennink, The Netherlands

HALL A

 
08:30-09:00
New generation oral contraceptive pills: Are they safe?
L. Shulman, USA
Debate: Progesterone only contraception, better or worse?
09:00-09:30 For: G. Merki-Feld, Switzerland
09:30-10:00 Against: T. Bombas, Portugal
10:00-10:30

Coffee Break at the exhibition

Session 14
10:30-12:30
NEW DEVELOPMENT AND A WINDOW TO A NEW FORMULA: WHO WOULD BENEFIT FROM IT?
Capsule: new estrogen and progestines are penetrating the market. Is there a real need for it?
Chairperson:S. Skouby, Denmark; J. Bitzer, Switzerland

HALL A

10:30-11:00
Estetrol for Oral Contraception – are we facing a safer formulation?
H. Coelingh Bennink, The Netherlands
11:00-11:30
NOMAC/E2: The next generation of oral contraception?
J. Bitzer, Switzerland
11:30-12:30
Debate: Emergency contraception: What should be used?
Ulipristal acetate vs. Levonorgestrel for emergency contraception: A. Ber, Israel
Short acting GnRH antagonist: Z. Shoham, Israel
IUD: A neglected option: F. Martinez, Spain
12:30-13:00 LUNCH at the exhibition
13:00-13:50
Symposium: 
 
HOT TOPICS
Chairpersons: Z. Shoham, Israel, M. Hod, Israel 
13:00-13:25
 

13:25-13:50
 

13:50-14:00

Making human ova  from Stem Cells
E. Telfer, Scotland

Does the risk of congenital malformation vary by mode of infertility treatment?
M. Davies, Australia
__________________________________________________________________
 
Abbott's award for best abstracts
Session 15
14:00-16:00
WHI DATA THROUGH THE MAGNIFYING GLASS: A DECADE-LONG DEBATE
Organized by IMS & in collaboration with EMAS & APMF
Chairpersons: T. de Villiers, South Africa; A. Pines, Israel

HALL A

14:00-14:30
Strengths and weaknesses of WHI: Methodological perspectives
R. Langer, USA
14:30-15:00
Recent guidelines and recommendations on hormone replacement therapy
T. de Villiers, South Africa
15:00-16:00
Panel Discussion: Has the time come to reach a consensus on hormone replacement therapy?
Delegates from the major menopause societies, aiming at defining the aspects which are globally agreed and the still existing un-bridged issues. Iit will be divided into chapters with separate discussions, such as on indications, length of Tx, low-dose, E-only, Tx of early menopause, risks of Tx, development of treatment algorhithms.
T. de Villiers, South Africa (IMS)
F.O. Liew, Malaysia (APMF)
S. Palacios, Spain
S. Rozenberg, Belgium (EMAS)
 
16:00-16:30
Coffee Break the exhibition
Session 16
16:30-18:00
HORMONE REPLACEMENT THERAPY: PERSPECTIVES OF 2012
Organized by IMS & in collaboration with EMAS & APMF &  partially supported by Besins Healthcare
Chairpersons: S. Rozenberg, Belgium; A. Pines, Israel 

HALL A

16:30-16:50
A world without hormone replacement therapy, fact or fiction?
S. Rozenberg, Belgium
16:50-17:10
Breast cancer risk strikes out hormone replacement therapy
A. Gompel, France
17:10-18:00
Debate: Back to oestrogen-only therapy?
Pro: M. Birkhäuser, Switzerland
Con: J. Stevenson, UK
 
Saturday, May 5, 2012 PERINATOLOGY
Session 17
08:30-10:00
CONTROVERSIES TO CONSENSUS
HOT TOPICS IN PERINATAL MEDICINE: PET AND FETAL CONGENITAL ANOMALIES
Chairperson: I. Meizner, Israel; L. Cabero, Spain

HALL B

08:30-09:10
Debate: Routine fetal anomaly screening in the first, second and third trimesters of all pregnancies?
One anomaly scan is adequate: K. Bilardo, The Netherlands
Three anomaly scans are the ideal way to examine the fetus: Y. Zalel, Israel
Routine  transvaginal scan at 20 weeks?:  E. Carreras Moratonas, Spain
09:10-09:30 Discussion
Moderator: I. Meizner, Israel
09:30-09:50 Debate: Prediction and prevention of preeclampsia
Yes: Prediction and prevention is possible: H. Valensise, Italy
No: Preeclampsia is unpredictable: F. Figueras, Spain
09:50-10:10 Discussion
Moderator: L. Cabero, Spain
10:10-10:30 Chairperson’s overview: Towards a consensus
10:00-10:30

Coffee Break at the exhibition

Session 18
10:30-12:30
CONTROVERSIES TO CONSENSUS: HOT TOPICS IN MATERNAL FETAL MEDICINE
All you can get on FGR
Chairperson: A. Wiznitzer, Israel; G. Visser, The Netherlands

HALL B

10:30-10:45 Developmental origins of adult disease: Impact on perinatal medicine
U. Simeoni, France
10:45-11:00 The definition and diagnosis of SGA
G. Visser, The Netherlands
11:00-11:15 Is IUGR predictable and preventable?
M. Ben-Ami, Israel
11:15-11:30
Early versus late onset FGR: Are they different?
E. Gratacós, Spain
11:30-11:45
FGR remote from term/near term: Delivery vs. Expectant management
N. Melamed , Israel
11:45-12:00
 
12:00-12:30
Should genetic counseling be part of the diagnostic work up near term?
T. H. Bui, Sweden
Q&A

12:30-13:00

LUNCH at the exhibition
13:00-13:50
Symposium: (HALL A)
 
HOT TOPICS
13:00-13:25
 

13:25-13:50
 


13:50-14:00
Making human ova  from Stem Cells
E. Telfer, Scotland
 
Does the risk of congenital malformation vary by mode of infertility treatment?
M. Davies, Australia
_____________________________________________________________________
 
Abbott's award for best abstracts (HALL A)
Session 19
14:00-16:00
THE PERINATAL TRIBUNAL
PROCESSING THE NOVEL APPROACH  TO DIABETIC  PREGNANCY
The Honorable Judge: M. Hod, Israel; H. Valensise, Italy

HALL B

GDM diagnosis
Case 1: Gestational diabetes is over diagnosed and over treated
14:00-14:10 Yes: It's over diagnosed and over treated: R. Corcoy, Spain
14:10-14:20
No: It's NOT over diagnosed and over treated: D. McIntyre, Australia
Court appointed expert: A. Kapur, Denmark
Treatment during pregnancy
Case 2: Can oral hypoglycaemic agents be used throughout pregnancy?
14:20-14:30 The Defence: Yes, OHA can be used: Y. Yogev, Israel
14:30-14:50 The Prosecution: No, OHA cannot be used: A. Lapolla, Italy
Court appointed expert: N. Lohse, Denmark
14:50-15:20 State of the art lecture: The use of insulin analogues in diabetic pregnancy
M. Hod, Israel
Delivery
Case 3: Should we deliver all diabetic patients by CS? Is there an estimated fetal weight cut off?
15:20-15:30 Yes: S. Alberico, Italy
15:30-15:40 No: G. Visser, The Netherlands
Court appointed expert: A. Antsaklis, Greece
15:40-16:00 Discussion
The Jury: Congress Participants
The Verdict: The Honourable Judges
16:00-16:30

Coffee Break at the exhibition

Session 20
16:30-18:00
CONTROVERSIES TO CONSENSUS: NOVEL APPROACH TO MULTIPLE PREGNANCIES
Chairpersons: E. Gratacós, Spain; G. Visser, The Netherlands

HALL B

16:30-16:45 MC twins: Should termination be offered? 
I. Blickstein, Israel
16:45-17:00 Reduction from twins to singleton (MC and DC)?
M. Evans
, USA
17:00-17:15
Management of growth restriction in MC pregnancy
E. Gratacós, Spain
17:15-17:30 The risk of perinatal complications in DC twins
E. Llurba, Spain
17:30-17:50
Debate: How and when to deliver MC and BC twins?
Moderators: E. Gratacós, Spain; G. Visser, The Netherlands
I. Blickstein, Israel
M. Evans, USA
E. Gratacós, Spain
E. Llubra, Spain
17:50-17:55 Discussion
17:55-18:00 Chairperson's overview: Towards a consensus
 
Saturday, May 5, 2012 ■ REPRODUCTIVE MEDICINE & ART
Session 21
08:30-10:00
PRE-CONCEPTION GENETIC DIAGNOSIS AND PGD
Capsule: Advances in genomics currently allow for the screening of hundreds of genetic diseases. This may allow us to eliminate the risk for most inherited diseases but also makes very easy the selection of other traits.
Chairperson: S. Munné, USA

HALL C

08:30-09:00 Preconception genetics for IVF patients and gamete donation
S. Munné, USA
09:00-10:00
Debate: European for PBs, USA for blastocysts
Preconception genetic diagnosis followed by PGD are the right time to screen for genetic diseases, and not prenatal diagnosis
M. Hughes, USA
Whole genome sequencing is easy – but who will make sense of it?
Mark Evans, USA
Does PGS increase live birth rate? The pendulum of PGS
S. Fishel, UK
10:00-10:30
Coffee Break at the exhibition
Session 22
10:30-12:30
LUTEAL PHASE SUPPORT
Chairpersons: R. Aurell, Spain; A. Weissman, Israel
10:30-11:00 Overview of the luteal phase with emphasis on early introduction of progesterone
TBA
11:00-12:00
Debate: What should be the preferred route for progesterone administration?
IM route: N. Gleicher, USA
Vaginal products: TBA
12:00-12:30
Estrogen and GnRH agonists for luteal support
G. Grudzinskas, UK
12:30-13:00

LUNCH at the exhibition

13:00-13:50
Symposium: (HALL A)
 
HOT TOPICS
13:00-13:25


13:25-
13:50


13:50-14:00
Making human ova from Stem Cells
E. Telfer, Scotland

Does the risk of congenital malformation vary by mode of infertility treatment?
M. Davies, Australia
_____________________________________________________
 
Abbott's award for best abstracts (HALL A)
Session 23
14:00-16:00
IVM
Capsule: Is it still an experimental procedure? Why has it not become common practice in IVF?
Chairpersons: M. Leong, China; G. Schatten, USA

HALL C

14:00-15:00

Debate

IVM as an alternative to FSH IUI for treatment of infertility: S.L. Tan, Canada

IVM for selected group of patients only: M. Leong, China

15:00-15:30 Oocytes generated in vitro: What are the strengths and limitations of artificial gametes?
G. Schatten, USA
15:30-16:00 Is there an optimal stimulation protocol? Optimal number of oocytes to achieve a pregnancy
P. Barri, Spain
16:00-16:30

Coffee Break at the exhibition

Session 24
16:30-18:00
HOW SHOULD WE EVALUATE THE OOCYTE DURING ART?
Chairpersons: I. Tur-Kaspa, USA

HALL C

16:30-17:00 Oocyte competence for fertilization: What are the events vital to complete maturation?
G. Schatten, USA
17:00-17:30 Predicting oocyte competence by polar body chromosome analysis
S. Fishel, UK
17:30-18:00
The follicle and oocyte competence: Does size or volume matter?
A. Revelli, Italy
 

Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 05/16/2012 Created by     WebStudio.co.il